Parabilis Medicines ended its first day of trading on the Nasdaq Global Select Market with shares up 58%, pushing the biotech's market capitalization to roughly $3.7 billion.¹

The company’s performance exceeded the $2.2 billion valuation it had initially targeted when it filed to go public.

The surge capped a record-breaking public debut, as Parabilis had originally proposed selling 25 million shares at between $17 and $19, but strong investor demand drove the offering to 33.5 million shares priced at $20 each, raising $670 million in gross proceeds and surpassing Kailera Therapeutics' $625 million April IPO to claim the title of largest-ever biotech IPO.²

Kailera, an obesity-focused clinical-stage company, had itself set the record when it priced 39 million shares at $16 in April 2026.² Before that, Moderna had held the benchmark with plans to raise up to $600 million in its own landmark debut.³

What is driving investor interest in Parabilis?

One of the potential key factors driving interest to Parabilis is zolucatetide, an investigational first-in-class inhibitor of the Wnt/β-catenin signaling pathway and the lead asset of the company's proprietary Helicon peptide platform.⁴ The drug is believed to be the first and only direct inhibitor of the β-catenin:TCF interaction, a protein-protein interaction long considered one of oncology's most consequential undruggable targets.

Zolucatetide works by penetrating cells and directly blocking the interaction between β-catenin and the T-cell factor family of transcription factors, the critical downstream node through which Wnt pathway mutations drive tumor growth. Because it acts as this downstream node rather than upstream in the signaling cascade, the drug is designed to block oncogenic signaling irrespective of the various APC and β-catenin mutations that typically cause disease, a potentially broad mechanism of action.⁴

FDA has granted zolucatetide both Orphan Drug Designation and Fast Track Designation for the treatment of desmoid tumors, a rare locally invasive soft tissue cancer for which no existing therapy targets the underlying biology.⁴ Orphan Drug Designation carries meaningful development incentives, including tax credits toward clinical trial costs, prescription drug user fee waivers, and up to seven years of regulatory exclusivity following approval.⁴

What does the clinical data show?

Early data first presented at the ESMO Congress and the Connective Tissue Oncology Society 2025 Annual Meeting showed zolucatetide produced a 100% disease control rate in all 10 desmoid tumor patients with at least one post-baseline scan, and an 80% objective response rate in the five patients with more than one post-baseline scan per RECIST 1.1.⁴ More recent data from the company's ongoing Phase I/II trial, in which more than 150 patients have been dosed to date, showed tumor reductions in 100% of 25 response-evaluable desmoid patients, with a 74% ORR in the 19 patients with at least two post-baseline scans.⁴

"Patients living with desmoid tumors have lacked therapies that directly address the root biological cause of their disease because that biology, the β-catenin:TCF interaction, has long been considered 'undruggable,'" said Mathai Mammen, MD, PhD, chairman, CEO, and president of Parabilis. "With compelling early clinical data showing encouraging evidence of clinical activity, we are building momentum behind zolucatetide as a potential first-in-class therapy that we believe could help redefine the standard of care for patients with desmoid tumors."3

Sources

1. Parabilis Medicines, Inc. Common Stock (PBLS) Yahoo Finance June 10, 2026 https://finance.yahoo.com/quote/PBLS/
2. Kailera Therapeutics Announces Pricing of Initial Public Offering Kailera April 16, 2026 https://www.globenewswire.com/news-release/2026/04/16/3275907/0/en/Kailera-Therapeutics-Announces-Pricing-of-Initial-Public-Offering.html
3. Moderna Therapeutics on path to becoming biggest US biotech IPO in history Proactive December 6, 2018 https://www.proactiveinvestors.com/companies/news/210712/moderna-therapeutics-on-path-to-becoming-biggest-us-biotech-ipo-in-history-210712.html?region=ca
4. Parabilis Medicines’ Zolucatetide, the First and Only Direct Inhibitor of the Elusive β-catenin:TCF Interaction, Receives FDA Orphan Drug Designation for the Treatment of Desmoid Tumors Parabilis Therapeutics March 11, 2026 https://investors.parabilismed.com/news-releases/news-release-details/parabilis-medicines-zolucatetide-first-and-only-direct-inhibitor